Imagine facing a blood cancer with few effective treatment options. B-cell malignancies, like marginal zone lymphoma and follicular lymphoma, can be tough to treat, leaving many patients searching for hope. A new drug called BGB-16673 is currently being tested in a clinical trial to find the right dose and ensure it’s safe for patients. This study is split into two parts: the first focuses on finding the maximum tolerated dose, while the second looks at how well the drug works in larger groups of patients. If BGB-16673 proves effective, it could become a new option for those who have been struggling with these difficult-to-treat cancers. However, it’s important to remember that this is still early research, and we need to see how patients respond to the treatment before we can make any conclusions. The journey ahead is filled with hope, and for many, this could mean a chance at a better quality of life.
Could This New Drug Offer Hope for Patients with Tough Blood Cancers?
Plain Language Summary
What this means for you:
BGB-16673 may be a promising new option for patients with challenging blood cancers, offering hope for better treatments. What this means for you:
BGB-16673 may be a promising new option for patients with challenging blood cancers, offering hope for better treatments. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE1/PHASE2
Condition(s): B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia
Intervention(s): BGB-16673 (DRUG)
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Detailed: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Primary Outcome(s): Phase 1: Number of Participants with Adverse Events (AEs); Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-16673; Phase 1: Recommended dose(s) for Expansion (RDFE) of BGB-16673
Enrollment: 614 (ESTIMATED)
Lead Sponsor: BeOne Medicines
Start: 2021-09-13 | Primary Completion: 2026-11